Royal Philips' ElastQ Imaging device earned market clearance from the Food and Drug Administration.
ElastQ aids in the diagnosis of various liver conditions, including hepatitis B and C, liver cancer and cirrhosis.
The device uses shear wave elastography to assess soft liver tissue for stiffness — a sign of issues with the organ — without the need for a liver biopsy.
ElastQ offers a larger field of vision, color-coded quantitative assessment of the tissue stiffness, and real-tine feedback and intelligent analysis, according to a news release.
More articles on supply chain:
Bernie Sanders introduces drug importation bill to lower medicine costs: 5 takeaways
Drug spending rose faster under ACA plans than other health plans
FDA: Drug manufacturing at Pfizer's Kansas plant is 'out of control'